VCC Adult Trials: LEUKEMIA

Acute Lymphoblastic Leukemia
Protocol CALGB 10403: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926

Chronic Lymphocytic Leukemia
Protocol CALGB 10404: A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926

Chronic Lymphocytic Leukemia
Protocol CALGB 10501: A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Patients Randomized To Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVH Unmutated Disease
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926

Acute Myelogenous Leukemia
Protocol CALGB 10603: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) Or Placebo in Newly Diagnosed Patients <60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)
Primary Investigator: Julian Sprague, M.D.
Contact: Jane Walsh, (802) 656-9926

Acute Myelogenous Leukemia
Protocol CALGB 10503: Phase II Study of Maintenance Therapy with Decitabine Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML<60 Years
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926

Acute Myelogenous Leukemia
Protocol ECOG 2902: A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926

Multiple Myeloma
Protocol CALGB 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813, IND #70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926

Multiple Myeloma
Protocol NovartisCZOL446E2105: A stratified, randomized, open-label, multi-center comparative 2-arm trial of PK, PD, and safety of Zometa infusions administered monthly vs. every 3-months, in multiple myeloma patients with malignant bone lesions, and breast cancer patients with bone metastasis, who have received 9 to 12 doses of Zometa over the prior year.
Primary Investigator: Barbara Grant, M.D.
Contact: Karen Lepuschenko, (802) 656-9924

Burkitt Lymphoma/Leukemia, Newly Diagnosed
Protocol CALGB 10002: A Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with CGSF Support in Previously Untreated Patients with Burkitt/Lymphoma/Leukemia.
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926